New hope for advanced cancer patients: first human trial of experimental oral drug begins
NCT ID NCT06260514
Summary
This is the first human study of an experimental oral medication called APR-1051 for people with advanced solid tumors that have spread or cannot be surgically removed. The main goals are to determine safe dosage levels, understand how the drug moves through the body, and look for early signs that it might help control cancer. The study will enroll 90 adults with various advanced cancers who have limited treatment options remaining.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center (MDACC)
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
NEXT Oncology -Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology -San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.